A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

NCT00051181 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Glaucoma, Angle-Closure
Ocular Hypertension

Interventions

DRUG: Travoprost (0.004%)
DRUG: Latanoprost (0.005%)

Sponsor

Alcon Research